- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00358709
Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Two State-of-the-Art Interventions
June 18, 2008 updated by: University of British Columbia
Treating Psychotic Symptoms of Young Individuals Presenting a First Episode of Schizophrenia: Comparison of Cognitive-Behavioral Therapy and Skills Training Symptom Management on Measures of Symptoms and on Other Indices of Well-Being
To verify the efficacy of a group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and to compare its effects to a known skills training approach and a control group.
Our primary hypotheses were that CBT would do better than the control group at all points in time, and better than the skills training approach, though only at follow-ups
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study's protocol has the following objectives: to verify the efficacy of a group CBT approach; to compare the effects of CBT to those of the symptom management module and to a control group on psychotic symptoms and subjective experiences (e.g., depression, anxiety, self-esteem, social support, insight, and coping); and to assess what the effects are related to, via measuring client variables, therapist variables, and intervention variables that might explain the results.
This study follows a randomized controlled trial design where participants are randomly assigned to one of the three groups at each recruiting wave.
Both treatment modalities hold the same number of group meetings as well as similar formats, lengths of treatment and operational structures, each operationalized in detailed manuals.
Interviewers are blind to group allocation.
Symptoms, both psychotic and otherwise, depression, self-esteem, social adaptation, anxiety, insight, social support, and coping are all measured before the beginning of treatment, three months follow-up, nine-months follow-up, and 15-months follow-up
Study Type
Interventional
Enrollment (Anticipated)
129
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Surrey, British Columbia, Canada
- Fraser Health Authority
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
1) less than two years since their first consultation in psychiatry for psychotic symptoms, 2) a DSM-IV diagnosis in the schizophrenia spectrum (or a psychotic episode suggesting a non-mood related psychosis), 3) ability to read and write in English, 4) aged between 18 and 35, 5) no organic disorder, and 6) consenting to participate
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Expected effects on symptoms, measured before beginning of treatment, three months, nine-months, and 15-months follow-ups
Time Frame: 15 months
|
15 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Self-esteem, social adaptation, coping, insight, substance abuse, measured before beginning treatment, three months, nine-months, and 15-months follow-ups
Time Frame: 15 months
|
15 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Tania Lecomte, The University of British Columbia
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2002
Primary Completion (Actual)
December 1, 2006
Study Completion (Actual)
December 1, 2006
Study Registration Dates
First Submitted
July 28, 2006
First Submitted That Met QC Criteria
July 28, 2006
First Posted (Estimate)
August 1, 2006
Study Record Updates
Last Update Posted (Estimate)
June 19, 2008
Last Update Submitted That Met QC Criteria
June 18, 2008
Last Verified
June 1, 2008
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B02-0769
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Fundació Institut de Recerca de l'Hospital de la...Recruiting
-
First Affiliated Hospital of Fujian Medical UniversityNot yet recruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Newron Pharmaceuticals SPARecruitingTreatment-resistant SchizophreniaUnited States, India
-
Bradley LegaRecruiting
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
All India Institute of Medical Sciences, BhubaneswarCompletedTreatment Resistant SchizophreniaIndia
-
Second Xiangya Hospital of Central South UniversityNot yet recruiting
-
Kaohsiung Medical University Chung-Ho Memorial...Not yet recruitingSchizophrenia Disorder
-
Shanghai Zhongze Therapeutics Co., Ltd.Yale UniversityNot yet recruiting
Clinical Trials on Cognitive-Behavioral therapy and Symptom Management
-
Stony Brook UniversityCompletedChronic Fatigue Syndrome | Medically Unexplained Chronic FatigueUnited States
-
Duke UniversityPalliative Care Research Cooperative GroupCompletedAdvanced CancerUnited States
-
Hannover Medical SchoolGerman Federal Ministry of Education and ResearchUnknownMedication Adherence | Rejection | Self ManagementGermany
-
University of LethbridgeRural Development NetworkRecruitingGambling DisorderCanada
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...Completed
-
University of British ColumbiaCompletedObsessive Compulsive DisorderCanada
-
Duke UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MarylandCompleted
-
Duke UniversityNational Cancer Institute (NCI)RecruitingHematologic MalignancyUnited States